- Home
- FT vs PLX Comparison
FT vs PLX Comparison
Compare FT & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- PLX
- Stock Information
- Founded
- FT 1988
- PLX 1993
- Country
- FT United States
- PLX United States
- Employees
- FT N/A
- PLX N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FT Finance
- PLX Health Care
- Exchange
- FT Nasdaq
- PLX Nasdaq
- Market Cap
- FT 200.8M
- PLX 204.9M
- IPO Year
- FT N/A
- PLX 1998
- Fundamental
- Price
- FT $7.96
- PLX $2.24
- Analyst Decision
- FT
- PLX Strong Buy
- Analyst Count
- FT 0
- PLX 1
- Target Price
- FT N/A
- PLX $15.00
- AVG Volume (30 Days)
- FT 63.0K
- PLX 981.1K
- Earning Date
- FT 01-01-0001
- PLX 11-13-2025
- Dividend Yield
- FT 7.85%
- PLX N/A
- EPS Growth
- FT N/A
- PLX N/A
- EPS
- FT N/A
- PLX 0.08
- Revenue
- FT N/A
- PLX $61,948,000.00
- Revenue This Year
- FT N/A
- PLX $14.53
- Revenue Next Year
- FT N/A
- PLX $75.77
- P/E Ratio
- FT N/A
- PLX $28.93
- Revenue Growth
- FT N/A
- PLX 62.79
- 52 Week Low
- FT $5.97
- PLX $1.16
- 52 Week High
- FT $7.23
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- FT 45.08
- PLX 49.05
- Support Level
- FT $7.91
- PLX $2.25
- Resistance Level
- FT $8.00
- PLX $2.40
- Average True Range (ATR)
- FT 0.08
- PLX 0.16
- MACD
- FT -0.01
- PLX -0.02
- Stochastic Oscillator
- FT 17.86
- PLX 68.00
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks. Withintheutilityportionoftheportfolio,wefocusoncompanieswithattractivedividendyieldsandwithahistoryofincreasingtheirdividends.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.